GeneDx Holdings Corp. (NASDAQ:WGS) Major Shareholder Sells $2,976,106.50 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) major shareholder Opko Health, Inc. sold 88,839 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $33.50, for a total value of $2,976,106.50. Following the sale, the insider now owns 2,984,564 shares in the company, valued at $99,982,894. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Opko Health, Inc. also recently made the following trade(s):

• On Monday, July 29th, Opko Health, Inc. sold 50,000 shares of GeneDx stock. The shares were sold at an average price of $33.86, for a total value of $1,693,000.00.
• On Friday, July 26th, Opko Health, Inc. sold 60,000 shares of GeneDx stock. The shares were sold at an average price of $33.85, for a total value of $2,031,000.00.
• On Wednesday, July 24th, Opko Health, Inc. sold 75,000 shares of GeneDx stock. The shares were sold at an average price of $33.72, for a total value of $2,529,000.00.
• On Monday, July 22nd, Opko Health, Inc. sold 50,000 shares of GeneDx stock. The shares were sold at an average price of $32.61, for a total value of $1,630,500.00.
• On Friday, July 19th, Opko Health, Inc. sold 25,000 shares of GeneDx stock. The stock was sold at an average price of $32.29, for a total value of $807,250.00.
• On Wednesday, July 17th, Opko Health, Inc. sold 25,000 shares of GeneDx stock. The stock was sold at an average price of $32.93, for a total value of $823,250.00.
• On Friday, July 5th, Opko Health, Inc. sold 36,118 shares of GeneDx stock. The stock was sold at an average price of $28.24, for a total value of $1,019,972.32.
• On Wednesday, July 3rd, Opko Health, Inc. sold 14,082 shares of GeneDx stock. The stock was sold at an average price of $28.23, for a total value of $397,534.86.
• On Monday, July 1st, Opko Health, Inc. sold 50,000 shares of GeneDx stock. The stock was sold at an average price of $26.63, for a total value of $1,331,500.00.

GeneDx Price Performance

WGS opened at $30.07 on Monday. The stock has a fifty day moving average of $28.43 and a 200-day moving average of $16.70. The firm has a market capitalization of $785.43 million, a P/E ratio of -5.81 and a beta of 2.29. GeneDx Holdings Corp. has a 12-month low of $1.16 and a 12-month high of $35.65. The company has a quick ratio of 2.99, a current ratio of 2.38 and a debt-to-equity ratio of 0.27.

Institutional Trading of GeneDx

Several hedge funds and other institutional investors have recently modified their holdings of the company. nVerses Capital LLC purchased a new stake in shares of GeneDx during the second quarter worth $50,000. Thompson Davis & CO. Inc. raised its holdings in shares of GeneDx by 20.8% during the first quarter. Thompson Davis & CO. Inc. now owns 24,094 shares of the company’s stock worth $220,000 after acquiring an additional 4,150 shares in the last quarter. PFG Investments LLC purchased a new stake in shares of GeneDx during the first quarter worth $95,000. Rhumbline Advisers raised its holdings in shares of GeneDx by 8,096.4% during the second quarter. Rhumbline Advisers now owns 18,360 shares of the company’s stock worth $480,000 after acquiring an additional 18,136 shares in the last quarter. Finally, Legal Advantage Investments Inc. purchased a new stake in shares of GeneDx during the second quarter worth $518,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on WGS shares. Craig Hallum raised their price objective on GeneDx from $43.00 to $46.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. TD Cowen raised their price objective on GeneDx from $46.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. BTIG Research raised their price objective on GeneDx from $35.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Jefferies Financial Group assumed coverage on GeneDx in a report on Monday, June 3rd. They issued a “hold” rating and a $21.00 target price for the company. Finally, The Goldman Sachs Group increased their target price on GeneDx from $28.00 to $32.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, GeneDx has an average rating of “Moderate Buy” and an average price target of $38.80.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.